ArticleFrontiers in pharmacology2022

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors.

Jianing Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.